All In Biotech

Drug Trial Radar · NCT05220917

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

781,430

Planned (sponsor's estimate)

Start

Aug 1, 2021

Primary completion

May 31, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; VA Boston Healthcare System; McGill University
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).

Conditions

  • Cardiovascular Events
  • Type2 Diabetes
  • Renal Disease

Interventions

  • SGLT2 inhibitorDrug

    Any SGLT2i dispensing claim

  • DPP-4 inhibitorDrug

    Any DPP-4 inhibitor claim

  • GLP-1RADrug

    Any SGLT2i dispensing claim

  • 2nd generation SUDrug

    Any 2nd generation SU claim

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MACETime frame: through study completion, an average of 1 year
  2. Modified MACETime frame: through study completion, an average of 1 year
  3. Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF)Time frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.